Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Empagliflozin/linagliptin - Boehringer Ingelheim

Next Previous
X
Search
Drug Profile

Empagliflozin/linagliptin - Boehringer Ingelheim

Alternative Names: Ajaduo; BI 10773/BI 1356; BI 10773/linagliptin; BI 1356/BI 10773; BI 1356/empagliflozin; Empa/Lina FDC; Empagliflozin/BI 1356; Glyxambi; Linagliptin/BI 10773; Linagliptin/empagliflozin; Tiptengio; Tradiance

Latest Information Update: 08 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Eli Lilly; Eli Lilly and Company
  • Class Alkynes; Antihyperglycaemics; Piperidines; Purines; Quinazolines; Small molecules
  • Mechanism of Action Dipeptidyl peptidase 4 inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 31 Dec 2022 Eli Lilly has patent protection for empagliflozin/linagliptin in USA until 2028
  • 08 Sep 2021 Launched for Type 2 diabetes mellitus in Malaysia, Turkey, Israel, United Kingdom, Philippines, Philippines, Canada, Russia, Australia, Greece, Austria, Switzerland, Poland, Spain, Netherlands, Sweden, Denmark, Hong Kong, Norway, Iceland (PO) prior to September 2021
  • 08 Sep 2021 Registered for Type 2 diabetes mellitus in Malaysia, Philippines, Canada, Russia, United Kingdom, Israel, Turkey, Australia, Switzerland, Hong Kong (PO) prior to September 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top